Skip to main navigation Skip to search Skip to main content

An International, Multicenter, Open-label Study of Vorinostat (MK-0683) in Combination with Bortezomib in Patients with Relapsed and Refractory Multiple Myeloma, Protocol 095-00

Upstate Medical University

Project: Research

Project Details

StatusFinished
Effective start/end date10/28/08 → 04/30/11

Funding

  • Merck and Company: $22,145.40